R
Ralexar Therapeutics
Ralexar Therapeutics is focused on the development of an innovative portfolio of liver X receptor agonists
About Ralexar Therapeutics
Ralexar Therapeutics, Inc. is a specialty pharmaceutical company established in 2014, with a focus on developing treatments for various dermatological conditions. Formerly known as Alexar Therapeutics, the company operates from its headquarters in Wayne, Pennsylvania. The firm's core strategy revolves around the development of topical and systemic therapies based on liver X receptor (LXR) modulators. These modulators target key pathways associated with skin disease, including immunologic, inflammatory, and barrier dysfunction.
The company's primary product candidate is ALX-101, a topical gel developed as an LXR agonist. This product is designed to deliver pharmacological activity directly to the skin with minimal systemic absorption, aiming to treat cutaneous inflammatory disorders such as atopic dermatitis. In 2017, Ralexar initiated a Phase 2b clinical study across approximately 30 centers in the United States to evaluate the efficacy of ALX-101 in adults and adolescents with moderate atopic dermatitis. The business model is centered on the clinical development and subsequent commercialization of its proprietary drug candidates, addressing significant unmet needs in the dermatology market. The company has successfully raised a total of $29.9 million in funding through multiple rounds, including Series A and Later Stage VC financing. Its investor base includes firms such as NeXeption, New Science Ventures, Third Point Ventures, Palo Alto Investors, and The Michael J. Fox Foundation.
The company's formation was driven by NeXeption, with entrepreneur Steve Tullman serving as the initial Chairman of the Board. Dave Pfeiffer has served as the President and Chief Executive Officer, leading the company through critical clinical development stages. One of the founders, Dr. Seth A. Rudnick, has an extensive background in the pharmaceutical and biotechnology industries. His career includes leadership roles at Schering-Plough, Biogen, and as CEO and Chairman of CytoTherapeutics. He was also instrumental in heading R&D at Johnson & Johnson's Ortho Biotech and has been a general partner at the venture capital firm Canaan Partners. Richard A. Serbin, another founder, possesses credentials in both pharmacy and law, with over 40 years of experience as an FDA Regulatory and Patent Attorney. His career includes key positions at Revlon and Johnson & Johnson, where he was Vice President of Corporate Development.
Source: Dealroom company dataNews
Open roles
Ralexar Therapeutics in the Malvern ecosystem
The Ralexar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
New Science Ventures
Third Point Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ralexar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ralexar Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


